Your shopping cart is currently empty

(S)-MRTX-1719 is the S-enantiomer of Navlimetostat and acts as a PRMT5/MTA complex inhibitor with an IC50 value of 7070 nM, enabling selective modulation of arginine methylation, epigenetic regulation, and transcriptional control, (S)-MRTX-1719 is widely applied in cancer epigenetics research to investigate PRMT5-dependent tumor growth and therapeutic vulnerabilities.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $996 | 10-14 weeks | 10-14 weeks | |
| 2 mg | $1,470 | 10-14 weeks | 10-14 weeks | |
| 5 mg | $2,320 | 10-14 weeks | 10-14 weeks |
| Description | (S)-MRTX-1719 is the S-enantiomer of Navlimetostat and acts as a PRMT5/MTA complex inhibitor with an IC50 value of 7070 nM, enabling selective modulation of arginine methylation, epigenetic regulation, and transcriptional control, (S)-MRTX-1719 is widely applied in cancer epigenetics research to investigate PRMT5-dependent tumor growth and therapeutic vulnerabilities. |
| In vitro | In MTAP-deleted cancer cells, (S)-MRTX-1719 exhibited MTA-dependent binding to PRMT5 and inhibited the methylation of cellular substrates (specifically SDMA) with an IC50 of < 10 nM [1]. |
| In vivo | In xenograft models such as HCT116 MTAP-/- and LU99, daily oral administration of (S)-MRTX-1719 resulted in tumor regressions. The efficacy correlates with the reduction of SDMA levels in tumor tissue. In contrast to early PRMT5 inhibitors, (S)-MRTX-1719 did not cause bone marrow toxicity at efficacious doses, as normal hematopoietic cells do not accumulate MTA, preventing the inhibition of PRMT5 in these tissues [1]. |
| Synonyms | (S)-Navlimetostat, (S)-MRTX1719, (S)-BMS-986504, (S)-BMS986504 |
| Molecular Weight | 464.88 |
| Formula | C23H18ClFN6O2 |
| Cas No. | 2630904-44-6 |
| Smiles | N#CC1=C(OC2CC2)C=C(Cl)C(F)=C1C3=C(C=NN3C)C=4C=CC=5C(=O)NN=C(C5C4)CN |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.